Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CONMED Corporation’s (NYSE: CNMD) U.S. Securities and Exchange Commission filings, with AI-powered tools to help interpret the information. CONMED files a variety of reports under the Securities Exchange Act of 1934, and its common stock is registered on the New York Stock Exchange under the symbol CNMD, as noted in multiple Form 8-K filings.
For this medical equipment company in the surgical and medical instrument manufacturing industry, SEC filings are a primary source for understanding its financial condition, operating performance and strategic actions. Current reports on Form 8-K disclose events such as quarterly and year-to-date financial results, portfolio optimization steps, changes in directors and executive officers, dividend declarations, and share repurchase authorizations. For example, recent 8-K filings describe the announcement of second and third quarter financial results, the intent to exit gastroenterology product lines, the appointment of a new independent director, the resignation of a director, the declaration of a quarterly cash dividend, and a planned transition of the Chief Financial Officer.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when accessed through this page, contain detailed financial statements, segment information for orthopedic and general surgery, and discussions of items that are later referenced in non-GAAP reconciliations, such as product rationalization costs, operational optimization consulting fees, executive transition costs, legal matters, contingent consideration fair value adjustments, restructuring and related costs, and other specified items. These filings also provide context for guidance on revenue and adjusted diluted earnings per share that CONMED discusses in its press releases and investor presentations.
In addition to giving direct access to the underlying documents, this page uses AI to summarize key points from lengthy filings, highlight important sections, and surface items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Users can review CONMED’s historical and current SEC disclosures here, along with AI-generated insights that explain the significance of each filing in clear language.
CONMED Corp executive Brent Lalomia exercised restricted stock units and received additional common shares as compensation. On March 6, 2026, 75 RSUs converted into 75 shares of common stock, and 26 of those shares were withheld at a price of $39.90 per share to cover tax obligations. After these transactions, Lalomia directly held 915.057 shares of CONMED common stock. A footnote also clarifies that prior reported holdings have been adjusted to exclude 140 shares that were previously reported in error.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that executive Matthew Schabacker, VP GM Advanced Surgical, received equity awards consisting of 9,827 restricted stock units and options to purchase 11,646 shares of common stock. The RSUs generally vest over three years, while the stock options generally vest in equal parts over four years.
Ferrell John D. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp Executive Vice President of HR John D. Ferrell reported equity awards in the form of restricted stock units and stock options. He was granted 9,282 RSUs, each representing one share of common stock, which generally vest over three years in 33%, 33%, and 34% annual installments. He also received options to purchase 10,999 shares of common stock, generally vesting in equal 25% installments over four years under the 2025 Long-Term Incentive Plan.
Pelletier Johonna Marie reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that Treasurer and VP, Tax Johonna Marie Pelletier received a grant of 5,896 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of CONMED common stock under the 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, encouraging multi‑year retention and alignment with shareholders.
SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp granted equity awards to executive Peter K. Shagory, EVP, Strategy & Corporate Development. He received 9,282 RSUs (Restricted Stock Units), each representing one future share of common stock, under the company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years from the March 2, 2026 grant date. He was also granted 10,999 stock options under the same plan, which generally vest in equal 25% installments over four years, starting one year after the grant date.
CONMED Corp executive Brent Lalomia reported equity awards that increase his stake-based compensation. On March 2, 2026, he acquired 9,554 RSUs, each representing one future share of common stock, and 11,322 stock options granted at no cost per option.
The RSUs generally vest over three years in 33%, 33%, and 34% annual installments, while the options generally vest in four equal annual installments. Both awards were granted under CONMED’s 2025 Long-Term Incentive Plan, tying a portion of his compensation to the company’s longer-term performance.
Foust Hollie K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that its General Counsel and Corporate Secretary, Hollie K. Foust, received equity awards in the form of restricted stock units and stock options. The grant included 10,919 RSUs, each representing a right to receive one share of CONMED common stock.
The RSUs were awarded under the company’s 2025 Long-Term Incentive Plan and generally vest over three years, with 33% vesting after the first and second years and 34% after the third year. Foust was also granted 12,940 options to purchase common stock under the same plan, which generally vest in equal 25% installments over four years starting one year after the grant date.
CONMED Corp reported that VP Corporate Controller Andrew James Moller acquired 5,896 restricted stock units (RSUs) as a grant of equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and the remaining 34% after three years, subject to the terms of the company’s 2025 Long-Term Incentive Plan.
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received new equity awards, increasing her direct holdings through compensation grants rather than open‑market trades. On March 2, 2026, she was granted 28,800 RSUs, each representing a right to one CONMED common share, and 68,258 stock options.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% the second year, and 34% the third year under CONMED’s 2025 Long-Term Incentive Plan. The stock options were also granted under the 2025 plan and generally vest in equal 25% installments over four years, beginning one year after the grant date.
CONMED Corp director Mark Kaye reported acquiring 152 shares of common stock through the exercise and conversion of 152 RSUs on February 24, 2026. Each RSU represents a right to receive one share of common stock under the company’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.
The RSUs generally vest 100% after one year, with vesting accelerated immediately if the director’s service terminates. After this transaction, Kaye directly holds 152 shares of CONMED common stock.